Description

Pramipexole Tablets (0.125 mg / 0.25 mg / 0.5 mg / 1 mg)

Healthy Inc is a specialized global supplier and exporter of advanced neurology, central nervous system (CNS), and geriatric therapeutics. We provide ultra-high-purity, kinetically precise Pramipexole Dihydrochloride Monohydrate Tablets (0.125 mg / 0.25 mg / 0.5 mg / 1 mg), manufactured in WHO–GMP certified, high-precision oral solid dosage facilities. This “Non-Ergoline Dopamine Agonist” is a highly lucrative, massive-volume export to neurology centers, sleep medicine clinics, geriatric care networks, and government health ministries in LATAM, the CIS, Africa, and Southeast Asia, serving as the globally mandated intervention for idiopathic Parkinson’s Disease and severe Restless Legs Syndrome (RLS).

Product Overview

This highly advanced formulation contains Pramipexole, a potent, synthetic dopamine mimic that physically crosses the blood-brain barrier to restore lost motor control and quiet agonizing neurological misfirings.

The “D3-Receptor & Restless Legs” Specialist:

• Mechanism 1 (The Direct Dopaminergic Drive): In Parkinson’s Disease, the neurons in the substantia nigra that produce dopamine are actively dying, severely impairing the patient’s ability to move smoothly. Pramipexole completely bypasses these dying cells. It acts as a direct, highly potent agonist at the D2 and D3 dopamine receptors in the striatum, physically tricking the brain into receiving the dopamine signals it is missing, drastically reducing tremors, bradykinesia (slowness), and extreme muscle rigidity.
• Mechanism 2 (The RLS Champion): Restless Legs Syndrome (RLS) is a severe neurological sensorimotor disorder characterized by an irresistible, agonizing urge to move the legs, particularly at night. Pramipexole’s unusually high affinity for D3 receptors makes it the premier, globally mandated therapy for RLS. A microscopic dose taken before bedtime completely quiets the nervous system, allowing patients to finally achieve restful sleep.
• The “Levodopa-Sparing” Advantage: Neurologists aggressively prescribe Pramipexole as an early, first-line monotherapy to delay the introduction of Levodopa. By preserving Levodopa for later stages of the disease, it significantly delays the onset of severe, irreversible motor complications and dyskinesia (involuntary jerking) later in the patient’s life.

Product Composition & Strength

We supply this product as a Precision-Blended Uncoated Tablet, packed exclusively in highly secure, moisture-resistant Alu-Alu blister strips to ensure the absolute chemical stability of the highly light-sensitive dihydrochloride monohydrate salt.

*Pack Sizes: 10×10 Alu-Alu Blisters or 3×10 Unit-Dose Blisters (Optimized specifically for strict, high-compliance chronic neurology dispensing and complex titration regimens).

Technical & Logistics Specifications

Critical data for Pharmaceutical Importers, Neurology Distributors, and Hospital Procurement Boards.

Manufacturing Authority

Marketed and Distributed by Healthy Inc from WHO-GMP & ISO 9001:2015 certified units.

• Extreme Micro-Dose Geometric Blending (CRITICAL COMPLIANCE): Manufacturing a 0.125 mg dose requires elite, state-of-the-art pharmaceutical engineering. Distributing such a microscopic fraction of a milligram uniformly throughout a standard tablet matrix presents a severe blending challenge. Our facilities utilize advanced high-shear homogenizers and strict, multi-stage geometric dilution protocols. This is rigorously verified by high-frequency HPLC content uniformity testing to guarantee that every single tablet delivers the exact fractional dose, completely eliminating the risk of catastrophic dopaminergic over-dosing (causing psychosis/syncope) or sub-therapeutic clinical failures.

Therapeutic Indications (Human Use)

Indicated for the targeted management of severe neurological motor and sensorimotor dysfunction:

• Parkinson’s Disease: Treatment of the signs and symptoms of idiopathic Parkinson’s disease. May be used as early monotherapy or as an adjunct to Levodopa therapy to smooth out “on-off” motor fluctuations in advanced disease.
• Restless Legs Syndrome (RLS): Treatment of moderate-to-severe primary Restless Legs Syndrome.

Dosage & Administration

Recommended Dosage (Strictly as per Neurologist Guidelines):

• Parkinson’s Disease (Titration is Mandatory): Must be initiated slowly at 0.125 mg three times a day (TID). The dose is gradually titrated upward every 5 to 7 days based on efficacy and tolerability, up to a maximum of 4.5 mg per day.
• Restless Legs Syndrome (RLS): 0.125 mg taken once daily, exactly 2 to 3 hours before bedtime. For patients requiring additional relief, the dose may be increased every 4-7 days up to a maximum of 0.5 mg per day.
• Discontinuation: Pramipexole must be tapered off slowly over several days to prevent Neuroleptic Malignant Syndrome (NMS)-like symptoms (high fever, severe muscle rigidity, altered consciousness).

Safety Warnings (CRITICAL Regulatory & Clinical Data):

• Sudden Sleep Onset (Sleep Attacks): Patients have reported falling asleep suddenly while engaged in daily activities, including operating motor vehicles, sometimes without any prior warning signs of drowsiness. Patients must be heavily warned about driving or operating heavy machinery.
• Impulse Control Disorders (Signature D3 Side Effect): Because Pramipexole aggressively stimulates the brain’s reward centers (D3 receptors), a highly significant number of patients develop intense, uncontrollable urges. This most commonly manifests as pathological gambling, hypersexuality, binge eating, or compulsive shopping. These behaviors usually resolve entirely when the dose is reduced or stopped.
• Orthostatic Hypotension & Syncope: Dopamine agonists severely impact blood pressure regulation. Patients, especially during dose escalation, can experience a sudden, massive blood pressure drop upon standing, leading to fainting (syncope) and severe fall injuries.
• Hallucinations & Psychosis: High levels of dopaminergic stimulation can trigger severe visual and auditory hallucinations, paranoia, and confusion, particularly in elderly patients with advanced Parkinson’s.

Global Export & Contract Manufacturing Services

Healthy Inc stands as a premier Pharmaceutical Exporter in India, dedicated to serving international Pharma Traders, Wholesalers, and Retail Pharmacy Networks. As a verified Medicine Supplier in Mumbai, we offer flexible Third Party Manufacturing (Contract Manufacturing) services for Advanced Neurological and Micro-Dosed Formulations. Whether you are looking for a reliable Hospital Tender Supplier for Parkinson’s clinics in Africa or a B2B Pharma Marketplace partner for Latin America, our logistics network ensures timely delivery. We actively support Pharmaceutical Bulk Indenting, ensuring that every Authorized Medicine Wholesaler receives WHO-GMP certified products at competitive rates.